Company profile ALVO

Alvotech
alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house develo...pment and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a Show More
Quarter analysis & expected interest

There is not enough data for Alvotech drug manufacturers to provide analysis

Correlation between past revenue and Alvotech drug manufacturers search interest

There is not enough data for Alvotech drug manufacturers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech drug manufacturers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech biosimilar medicines to provide analysis

Correlation between past revenue and Alvotech biosimilar medicines search interest

There is not enough data for Alvotech biosimilar medicines to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech biosimilar medicines to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT02 Humira biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT02 Humira biosimilar search interest

There is not enough data for Alvotech AVT02 Humira biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT02 Humira biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT04 Stelara biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT04 Stelara biosimilar search interest

There is not enough data for Alvotech AVT04 Stelara biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT04 Stelara biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT06 Eylea biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT06 Eylea biosimilar search interest

There is not enough data for Alvotech AVT06 Eylea biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT06 Eylea biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT03 Xgeva Prolia biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT03 Xgeva Prolia biosimilar search interest

There is not enough data for Alvotech AVT03 Xgeva Prolia biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT03 Xgeva Prolia biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT05 Simponi biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT05 Simponi biosimilar search interest

There is not enough data for Alvotech AVT05 Simponi biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT05 Simponi biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT16 immunology biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT16 immunology biosimilar search interest

There is not enough data for Alvotech AVT16 immunology biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT16 immunology biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT23 Xolair biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT23 Xolair biosimilar search interest

There is not enough data for Alvotech AVT23 Xolair biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT23 Xolair biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Alvotech AVT33 oncology biosimilar to provide analysis

Correlation between past revenue and Alvotech AVT33 oncology biosimilar search interest

There is not enough data for Alvotech AVT33 oncology biosimilar to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Alvotech AVT33 oncology biosimilar to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ALVO
Earnings date: 2024-02-28 After close
Company name: Alvotech
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-11T08:30:00Z

GlobeNewswire
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

2026-05-06T20:30:00Z

GlobeNewswire
Alvotech Q1 2026 Financial Results

2026-04-30T20:30:00Z

GlobeNewswire
Alvotech Announces a Change in its Executive Team

2026-04-24T12:30:00Z

GlobeNewswire
Alvotech to Report Financial Results for the First Quarter of 2026

2026-03-30T23:55:00Z

GlobeNewswire
Alvotech Files Annual Report with the SEC

2026-03-24T14:36:11Z

Analyst Upgrades
UBS Maintains Buy on Alvotech, Lowers Price Target to $6

2026-03-24T14:03:34Z

Analyst Upgrades
Barclays Maintains Underweight on Alvotech, Lowers Price Target to $4

2026-03-04T08:00:00Z

GlobeNewswire
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

2026-02-09T03:02:00-05:00

PR Newswire
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

2026-02-05T08:00:00Z

GlobeNewswire
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

2026-02-02T08:00:00Z

GlobeNewswire
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

2026-01-29T08:00:00Z

GlobeNewswire
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg

2026-01-20T17:30:00-05:00

PR Newswire
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

2026-01-15T18:35:00-05:00

PR Newswire
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

2026-01-14T14:30:00-05:00

PR Newswire
ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech (ALVO) for Potential Securities Fraud Following Massive FDA-Induced Stock Crash